Cytek jury verdict: noninfringement on 3 of 4 patent claims, $56.11M damages on 1 claim; appeal planned

Cytek Biosciences, Inc.

• Jury found for Cytek on 3 of 4 asserted claims (noninfringement and invalidity).
• One claim infringed under doctrine of equivalents; damages: $20M lost profits + $36.11M royalties.
• Cytek will pursue post-verdict motions and potential appeal to Federal Circuit.
• Verdict requires no changes to current products; spectral flow cytometry remains available globally.
• CEO Wenbin Jiang says Cytek developed fundamentally different Full Spectrum Profiling technology.